Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Learn the scenarios where index funds tend to outperform actively managed funds and the factors that drive these outcomes.
15,347 articlesAs GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Wheels Up Experience is in the spotlight as its stock faces a sharp decline. This article breaks down the primary cau...
A New York-based issuer sells rated notes backed by a pool of bitcoin-backed consumer loans, signaling a milestone fo...
United Parks & Resorts has seen a meaningful pullback this year, with a major fund exiting its position. This guide d...
When a bank’s CEO retiires and a director sells shares, investors take notice. This article breaks down what that mov...
Crypto ETPs face a five-week pullback totaling about $4 billion as volumes sink to 2025 lows. Market watchers warn th...
Premium concert seats can test budgets, but smart planning makes live music affordable. This guide breaks down pricin...
Bitcoin faces a sharp deleveraging as more than $370 million in liquidations hit long bets, while corporate buyers mo...
Option Care earnings season sheds light on the shifting landscape of home infusion and specialty care. This guide bre...
Grail stock showed a notable bounce after several tough sessions tied to trial updates. This piece breaks down what’s...
When a global pop star talks about blocking artists on Spotify, it’s more than a mood—it’s a real-world lesson in bud...
Markets shift, and healthcare REITs face unique pressures. This guide helps you decide if it’s time dump your shares ...